|
|
|
|
||
Re: Critical support ~$17.00 TPIV - Their balance sheet is a disaster and it's not clear how far they can go with the cash they have. Thank you. I never looked at their balance sheet nor even examined their technology to any degree but have looked at them occasionally for years. Seemed to me there might be something there. Please understand I am a dump picker. I first noticed ADXS and even went to its very first annual meeting so long ago it must have been in another millenium. An eager, naive young CEO had picked up what nobody else on the planet wanted, borrowed money for a Phase I from the most notorious financial predator at the time [Cornell], had a huge success and left a bled-out corpse still piling up interest. Not a great beginning I think most anyone would agree and there were a lot more troubles ahead. But science may yet win one. Hope so anyway. BTW ADXS had it easy compared to my second favorite - INSY - but that is a real life soap opera beyond compare. I think ADXS will have enough trouble dealing with the CAR-T world My worthless opinion is CAR-T may be a hot house flower unable to live in the real world but of some credibility is that of people who actually may know something: Renier J. Brentjens, MD, PhD, focuses on the development of new therapies for patients with acute and chronic leukemias, in particular on novel immunotherapies such as chimeric antigen receptor (CAR) T cells. He is one of the founders of Juno Therapeutics, a start-up company launched in 2013 to expand cell-based immunotherapies, including CD19-targeted CAR T cells, into multiple cancer types... Why has CAR T-cell therapy focused on CD19 thus far?It’s going to be interesting in the coming years to see whether the data that we have with these CD19-targeted CAR T cells in acute lymphoblastic leukemia (ALL) are the proof of principle for this technology or whether that is the only disease that this therapy will work in. What has to happen now, and is already happening, is that our group and others are targeting antigens on solid tumors. There is now a strong push to move this technology forward to see if we can get some promising clinical results in solid tumors, like breast cancer, prostate cancer, ovarian cancer, and so on. Time will tell whether similar striking results can be obtained in other tumors. I suspect we will see that, but I also suspect that we need to understand more about tumor biology and tumor immunology to find ways to make the T cells more potent than they currently are to have success in solid tumors.What are the most significant limitations to CD19-targeted therapy?The CAR T-cell technology does have significant side effects, specifically what we call cytokine release syndrome. So there are some issues regarding management of toxicity with this therapy that need to be addressed.Then, I think there is also the issue of how well this technology works in other B-cell cancers. In our hands, it doesn’t work anywhere near as well in patients with chronic lymphocytic leukemia, especially if they have bulky disease. So, although I think the technology is extremely promising, to be universally applicable to all CD19-positive tumors, I still think further modifications have to be made to make the cells more potent to eradicate certain types of B-cell cancers. That sounds to me to be considerably less than a ringing endorsement by a scientist heavily invested in the technology. now [ADXS] faces NantKwest (NK) with its killer cell oncology therapeutic technology. Please be so kind as to notice I have not denied any other technology. I just make amateur value judgments that sometimes work out. Best, Terry |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
857 | Re: Critical support ~$17.00 | meishairwin | 0 | 7/29/2015 7:09:11 AM |